GlassScriptPhysician profile
Jeffrey Conklin
NPI 1265513238
$2,364.92
in general payments reported to CMS, 2019-2025
29 companies · $236 in 2025
The $236 reported for 2025 was more than what a typical Adolescent Medicine (Internal Medicine) provider received nationally (typical 2025 total: $165).
See the full distribution for Adolescent Medicine (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $819 · 2020: $304 · 2021: $258 · 2022: $199 · 2023: $360 · 2024: $189 · 2025: $236.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $785.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $785.34 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $550.46 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Abbvie INC. | $292.70 | 2019-2025 | Qulipta, Ubrelvy, Vraylar |
| Pfizer INC. | $244.59 | 2019-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $186.26 | 2019-2025 | Xifaxan, Trulance |
| Abbott Laboratories | $150.75 | 2019-2025 | Freestyle Libre 3 |
| Genentech USA, INC. | $104.22 | 2019-2021 | |
| Lilly USA, LLC | $79.53 | 2019-2024 | Jardiance, Zepbound |
| Amgen INC. | $75.90 | 2020-2024 | Evenity, Prolia |
| Astrazeneca Pharmaceuticals LP | $74.40 | 2019-2020 | |
| Merck Sharp & Dohme LLC | $56.64 | 2019-2025 | Capvaxive |
| Teva Pharmaceuticals USA, INC. | $52.14 | 2019-2020 | |
| Takeda Pharmaceuticals U.S.A., INC. | $51.73 | 2019-2020 | |
| Amarin Pharma, INC. | $46.06 | 2019 | |
| Clarus Therapeutics INC. | $42.96 | 2021 | |
| Glaxosmithkline, LLC. | $42.35 | 2021-2025 | Arexvy, Shingrix |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kaleo, INC. | $37.58 | 2019-2020 | |
| Sanofi-Aventis U.S. LLC | $32.20 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $30.52 | 2019 | |
| Exact Sciences Corporation | $27.96 | 2023 | Cologuard Collection Kit |
| Novartis Pharmaceuticals Corporation | $25.95 | 2024 | |
| Sanofi Pasteur INC. | $23.78 | 2019 | |
| Optinose US, INC. | $20.03 | 2023 | |
| Gilead Sciences, INC. | $19.09 | 2019 | |
| Vyera Pharmaceuticals, LLC | $17.98 | 2019 | |
| Watermark Medical, INC. | $17.89 | 2024 | |
| Avion Pharmaceuticals | $16.73 | 2023 | Balcoltra |
| Biohaven Pharmaceuticals, INC. | $15.62 | 2021 | |
| Ironshore Pharmaceuticals INC. | $14.79 | 2019 | |
| Allergan, INC. | $14.11 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Conklin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.